Avirmax Inc

We are developing rAAV mediated gene therapeutics
Safe, Effective, Affordable and Accessible
Read More
We are developing rAAV mediated gene therapeutics
Safe, Effective, Affordable and Accessible
Read More
Previous
Next
About Us

Welcome to Avirmax Inc.

Avirmax, Inc. based in San Francisco Bay Area, is dedicated to the innovation, development, and manufacture of adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and Bac-to-AAV technologies. Avirmax’s AAV Innovation Platform, a robust streamlined assembly line of novel AAV vector discovery and development, enables us to become a powerhouse of rAAV therapeutics due to its highly transducible AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with effective, safe, long-acting AAV-mediated biotherapeutics in the most affordable and accessible manner possible.

TECHNOLOGIES

AAV Capsid Engineering

Enhanced GOI Expression

Generic rAAV Manufacturing Technologies

Product Pipeline

Avirmax is at the preclinical stage of biotherapeutics development using our rAAV delivery system. Currently, we are developing multiple candidate rAAV vectors. The following are examples of our product pipelines under development.

We have the best Services

Avirmax is at preclinical stage of biotherapeutics development using rAAV delivery system. Currently, it is developing multiple candidates lead rAAV vectors. The following listed in the table are examples of its product pipelines.